IDH1 and chondrosarcoma: Patients with Grade 2 chondrosarcoma had lower 2-year overall survival if they also presented with the IDH1 R132 mutation than those with the wild-type gene or other mutations (75% [95% CI 45% to 100%] versus 100% [95% CI 100% to 100%]; p = 0.04) (Fig. 3).